Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $86.38 +2.92 (+3.49%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About DexCom Stock (NASDAQ:DXCM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DexCom alerts:Sign Up Key Stats Today's Range$85.25▼$87.8850-Day Range$83.02▼$92.3452-Week Range$54.11▼$92.59Volume2.08 million shsAverage Volume4.98 million shsMarket Capitalization$32.60 billionP/E Ratio34.15Dividend YieldN/APrice Target$92.43Consensus RatingBuy Company Overview DexCom, Inc. (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions. The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting. Dexcom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin, including people seeking greater insight into how everyday activities affect glucose levels. Founded in 1999 and headquartered in San Diego, California, DexCom serves customers in the United States and international markets. Its products are distributed through healthcare providers, pharmacies, distributors and other commercial channels, with applications spanning diabetes management, remote monitoring and connected health.AI Generated. May Contain Errors. Read More DexCom Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreDXCM MarketRank™: 4.586058069575 of 5 starsDexCom scored higher than 92% of companies evaluated by MarketBeat, and ranked 24th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingBuy Consensus RatingDexCom has received a consensus rating of Buy. The company's average rating score is 3.04, and is based on 3 strong buy ratings, 19 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for DexCom is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageDexCom has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth16.67% Earnings GrowthEarnings for DexCom are expected to grow by 16.67% in the coming year, from $2.64 to $3.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 34.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.83.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 34.08, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.01.Price to Earnings Growth RatioDexCom has a PEG Ratio of 1.43. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 12.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.73% of the float of DexCom has been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 3.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 18.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.89 News SentimentDexCom has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for DexCom this week, compared to 9 articles on an average week.Search Interest14 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows4 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,945,875.00 in company stock.Percentage Held by Insiders0.28% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXCM Stock News HeadlinesDexCom gains as NEJM publication boosts Medicare coverage hopes6 minutes ago | seekingalpha.comLandmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on InsulinOctober 14 at 5:10 PM | businesswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 15 at 1:00 AM | Profits Run (Ad)Here's What to Expect From DexCom’s Next Earnings ReportOctober 13 at 6:31 AM | barchart.comDexCom (NASDAQ:DXCM) EVP Sells 2,565 Shares of Company StockOctober 1, 2026 | insidertrades.comOura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring (DXCM)Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.September 22, 2026 | marketbeat.comNicholas Augustinos Sells 1,550 Shares of DexCom (NASDAQ:DXCM) StockSeptember 17, 2026 | insidertrades.comInsider Selling: DexCom (NASDAQ:DXCM) EVP Sells 3,638 SharesSeptember 15, 2026 | insidertrades.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $66.37 at the beginning of the year. Since then, DXCM shares have increased by 29.8% and is now trading at $86.1350. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, July, 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. The company's revenue for the quarter was up 13.1% on a year-over-year basis. Read the conference call transcript. When did DexCom's stock split? Shares of DexCom split on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? DexCom subsidiaries include these companies: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? DexCom's top institutional shareholders include Gradient Investments LLC (0.06%), HWG Holdings LP (0.03%), Woodstock Corp (0.02%) and Bright Rock Capital Management LLC (0.01%). Insiders that own company stock include Jacob Steven Leach, Kevin R Sayer, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Jon Coleman, Jon Coleman, Barry J Regan, Steven R Altman, Mark G Foletta, Matthew Vincent Dolan, Richard Alexander Collins, Nicholas Augustinos, Bridgette P Heller and Kyle Malady. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Netflix (NFLX), Shopify (SHOP) and Salesforce (CRM). Company Calendar Last Earnings7/30/2026Today10/15/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DXCM's financial health is in the Green zone, according to TradeSmith. DXCM has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:DXCM CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees11,000Year Founded1999Price Target and Rating Average Price Target for DexCom$92.43 High Price Target$115.00 Low Price Target$75.00 Potential Upside/Downside+7.3%Consensus RatingBuy Rating Score (0-4)3.04 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$2.53 Trailing P/E Ratio34.09 Forward P/E Ratio32.64 P/E Growth1.43Net Income$836.30 million Net Margins20.12% Pretax Margin25.76% Return on Equity35.94% Return on Assets14.75% Debt Debt-to-Equity Ratio0.47 Current Ratio1.73 Quick Ratio1.43 Sales & Book Value Annual Sales$4.66 billion Price / Sales6.97 Cash Flow$2.80 per share Price / Cash Flow30.72 Book Value$7.04 per share Price / Book12.24Miscellaneous Outstanding Shares377,360,000Free Float376,304,000Market Cap$32.52 billion OptionableOptionable Beta1.48 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:DXCM) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
